Cyclophosphamide News and Research

RSS

Cyclophosphamide is a drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. It is also used to treat some types of kidney disease in children. Cyclophosphamide attaches to DNA in cells and may kill cancer cells. It is a type of alkylating agent. Also called CTX and Cytoxan.

Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.

PET scans accurately detect a breast tumor's response to chemotherapy

Researchers in Australia have shown that positron emission tomography (PET) that uses a radioactive sugar molecule is more useful than mammography and ultrasound in predicting a breast tumour's response to chemotherapy and, therefore, the patient's ultimate likelihood of survival.

26 Sep 2007

New combo treatment for chronic lymphocytic leukaemia increases survival

The combination treatment of fludarabine plus cyclophosphamide for chronic lymphocytic leukaemia (CLL) greatly increases progression-free survival and response rates, compared with single treatment with either fludarabine or chlorambucil alone.

20 Jul 2007

Promising new therapy for protecting the fertility of women with cancer

A promising new therapy for protecting the fertility of women with cancer and auto-immune diseases such as lupus was revealed at the 23rd annual conference of the European Society of Human Reproduction and Embryology.

4 Jul 2007

High frequency of sperm abnormalities associated with reduced testicular volume in male lupus patients

The prognosis for systemic lupus erythematosus (SLE), an autoimmune disease that mainly affects women in their reproductive years, has improved recently, prompting a shift toward improving quality of life.

29 Jun 2007

Study on B-cell depletion therapy

36% of patients with refractory systemic lupus erythematosus (SLE or lupus) remain well after undergoing B-cell depletion therapy (BCDT) without needing further standard immunosuppressive agents, according to a study presented at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.

17 Jun 2007

Herceptin does not increase heart failure in patients long-term

Risk of congestive heart failure in women treated with trastuzumab (Herceptin) and combination chemotherapy for early-stage breast cancer did not increase over time according to a five-year follow-up of National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31, presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

5 Jun 2007

Benefits of Herceptin are lasting

An updated analysis of two large randomized clinical trials has found that breast cancer patients who received the monoclonal antibody trastuzumab (Herceptin) along with chemotherapy are living longer and with less risk of recurrent disease, compared to patients treated with chemotherapy alone.

5 Jun 2007

Methods for treating lupus nephritis

Good patient information is essential for choosing the best treatment for the kidney disease lupus nephritis.

17 May 2007

Oncolytic viruses deliver a knockout punch to cancers

New scientific evidence is helping to build a compelling case for oncolytic viruses as a first-line and adjunctive treatment for many cancers.

11 May 2007

GlaxoSmithKline initiates study of PROMACTA in chronic idiopathic thrombocytopenic purpura

GlaxoSmithKline has announced the initiation of a global, open-label, single group trial that will assess the efficacy, safety and tolerability of PROMACTA (eltrombopag olamine) in patients previously treated for chronic idiopathic thrombocytopenic purpura (ITP).

15 Apr 2007

Researchers discover how cyclophosphamide chemotherapy drug helps a cancer-killing virus

Researchers here have discovered how a specific chemotherapy drug helps a cancer-killing virus. The virus is being tested in animals for the treatment of incurable human brain tumors.

31 Aug 2006

Biomira Stimuvax prostate cancer study results published

Biomira Inc. has announced publication of study results showing that Stimuvax, formerly known as BLP25 Liposome Vaccine or L-BLP25, could slow rising Prostate Specific Antigen (PSA) levels in some post-surgical prostate cancer patients

20 Jul 2006

Circulating bone-marrow derived cells do not contribute to egg formation

Ovulated egg cells, or oocytes, in adult female mice are not formed from germ cells in the blood or bone marrow.

14 Jun 2006

Benefit of chemotherapy in breast cancer depends on estrogen status of tumors

When it comes to chemotherapy treatment for women whose breast cancer has spread to their lymph nodes, the estrogen status of their tumors matters, says a team of researchers in the Journal of the American Medical Association.

11 Apr 2006

Combination therapy improves Acquired Immunodeficiency Syndrome-Related Lymphoma outcome

Combining aggressive HIV therapy and chemotherapy significantly improves the survival rates of HIV-positive men and women treated for lymphoma, according to a new study.

27 Feb 2006

Botox finds a use in cancer treatment

The cosmetic treatment Botox may have a new use as an adjuvant to cancer therapy, providing an open door for chemotherapy and radiation treatments, according to a study published in the Feb. 15 issue of Clinical Cancer Research.

17 Feb 2006

Mycophenolate mofetil helps treat lupus patients

Treating lupus patients suffering from kidney inflammation with a medicine known as mycophenolate mofetil may be more effective in inducing remission than treating them with the standard regimen of intravenous cyclophosphamide (Cytoxan), a new clinical trial indicates.

2 Dec 2005

New drug CellCept far more effective in treating kidney problems in lupus patients

A new study has shown that the drug CellCept is just as good at fighting kidney complications from the debilitating disease lupus with far fewer side effects than standard treatment using the cancer drug Cytoxan.

24 Nov 2005

New treatment advances for patients with follicular lymphoma

A newly published study recommends that doctors carefully choose their patients' initial therapies because there are significant differences in overall survival rates, according to researchers at the University of Rochester Medical Center's James P. Wilmot Cancer Center.

20 Oct 2005

Medulloblastoma irradiation may impair reading skills in young children

Irradiation therapy for the brain cancer medulloblastoma is more likely to impair IQ and reading skills of younger children than older children even if the dose of radiation is reduced, according to the results of the largest study of its kind, conducted by investigators at St. Jude Children's Research Hospital, Texas Children's Cancer Center (Houston) and Royal Children's Hospital (Melbourne, Australia).

22 Aug 2005